Cochrane · systematic review · CD010125

Aminoadamantanes for chronic hepatitis C

Lamers, MH, Broekman, M, Drenth, JPH, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library

Hepato-BiliaryAMSTAR 2: not assessed

SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.

Questions

current version

GRADE rated

No studies

Included studies

No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 28.6%Low 2 · 28.6%Moderate 3 · 42.9%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Comparison

Population: patients with chronic hepatitis C

7 questions

Outcome	Effect	Evidence	Status / GRADE
All‐cause mortality or liver‐related morbidity	RR 0.9 [0.38, 2.17]	32 studies · 4617 participants	Very low Downgraded: risk of bias, imprecision, indirectness
Adverse events	RR 0.98 [0.84, 1.14]	35 studies · 5646 participants	Moderate Downgraded: inconsistency, indirectness
Failure of end of treatment virological response Absence of clearance of HCV RNA from the blood at end of treatment	RR 0.95 [0.9, 1]	30 studies · 4861 participants	Moderate Downgraded: inconsistency, indirectness
Failure of sustained virological response Absence of clearance of HCV RNA from the blood 6 months after treatment	RR 0.98 [0.95, 1.02]	35 studies · 5582 participants	Moderate Downgraded: inconsistency, indirectness
Quality of life Different QoL scales	no estimate extracted	6 studies · 1181 participants	Very low
Failure of normalisation of ALT at end of treatment	RR 0.88 [0.83, 0.94]	19 studies · 2241 participants	Low Downgraded: inconsistency, indirectness
Failure of normalisation of ALT at end of	RR 0.95 [0.91, 1]	21 studies · 3744 participants	Low Downgraded: inconsistency, indirectness